CGIM
LCTX icon

Cannon Global Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Cannon Global Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,000
Closed -$29.9K – 82
2025
Q2 		$29.9K Buy
+33,000
New +$19.6K 0.06% 68

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cannon Global Investment Management's LCTX Position: Q3 2025 in Review

Cannon Global Investment Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 33,000 shares — an estimated $29.9K sold.

Cannon Global Investment Management first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $29.9K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Cannon Global Investment Management reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 33,000 Lineage Cell Therapeutics shares in Q3 2025, an estimated $29.9K.
  • Cannon Global Investment Management first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
  • Cannon Global Investment Management's Lineage Cell Therapeutics position peaked at $29.9K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Cannon Global Investment Management's 13F filing for Q3 2025, filed 28 Oct 2025.